ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,296.20
-0.32%
S&P ASX All Technology
4,030.80
-1.66%
Brent Oil
73.935
0.00%
US Dollar vs AUD
1.57307
0.00%
Bitcoin
95,522.20
-1.09%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Aquestive Therapeutics Inc (AQST) Share Price

Aquestive Therapeutics Inc

Aquestive Therapeutics Inc (AQST)

NASDAQ
3.01
-0.05
(-1.63%)
Closed 24 February 8:00AM
Delayed by 15 minutes
3.04
0.03
(1.00%)
After Hours: 10:49AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
3.04
Bid
2.98
Offer
3.04
Volume
1,422,747
3.01 Day's Range 3.15
2.24 52 Week Range 6.23
Market Cap
277.182M
Previous Close
3.06
Open
3.12
Last Trade
10
@
3.04
Last Trade Time
Financial Volume
US$ 4,372,664
VWAP
3.0734
Average Volume (3m)
1,726,791
Shares Outstanding
91,178,193
Dividend Yield
-
PE Ratio
-34.88
Earnings Per Share (EPS)
-0.09
Revenue
50.58M
Net Profit
-7.87M

About Aquestive Therapeutics Inc

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the t... Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.aquestive.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Aquestive Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AQST. The last closing price for Aquestive Therapeutics was US$3.06. Over the last year, Aquestive Therapeutics shares have traded in a share price range of US$ 2.24 to US$ 6.23.

Aquestive Therapeutics currently has 91,178,193 shares in issue. The market capitalisation of Aquestive Therapeutics is US$279.01 million. Aquestive Therapeutics has a price to earnings ratio (PE ratio) of -34.88.

Ask ADVFN Intelligence (AI)

Aquestive Therapeutics (AQST) Options Flow Summary

AQST Options Flow

Overall Flow

Bearish

Net Premium

-120k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

AQST Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
12 February 2025
AQST (-1.63%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
25 January 2025
AQST (-1.63%)

Form 8-K - Current report
Edgar (US Regulatory)
13 January 2025
AQST (-1.63%)

Form 8-K - Current report
Edgar (US Regulatory)
20 December 2024
AQST (-1.63%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.45-12.8939828083.493.542.9517178793.13038183CS
4-0.09-2.875399361023.133.632.8720454543.22268699CS
12-2.06-40.39215686275.15.2252.8717267913.46456113CS
26-1.3-29.95391705074.345.82.8714864694.18148272CS
520.3814.28571428572.666.232.2418509303.94520768CS
1560.624.59016393442.446.230.6189495233.10189241CS
260-1.33-30.43478260874.379.4650.6188712003.82980113CS

AQST - Frequently Asked Questions (FAQ)

What is the current Aquestive Therapeutics share price?
The current share price of Aquestive Therapeutics is US$ 3.04
How many Aquestive Therapeutics shares are in issue?
Aquestive Therapeutics has 91,178,193 shares in issue
What is the market cap of Aquestive Therapeutics?
The market capitalisation of Aquestive Therapeutics is USD 279.01M
What is the 1 year trading range for Aquestive Therapeutics share price?
Aquestive Therapeutics has traded in the range of US$ 2.24 to US$ 6.23 during the past year
What is the PE ratio of Aquestive Therapeutics?
The price to earnings ratio of Aquestive Therapeutics is -34.88
What is the cash to sales ratio of Aquestive Therapeutics?
The cash to sales ratio of Aquestive Therapeutics is 5.43
What is the reporting currency for Aquestive Therapeutics?
Aquestive Therapeutics reports financial results in USD
What is the latest annual turnover for Aquestive Therapeutics?
The latest annual turnover of Aquestive Therapeutics is USD 50.58M
What is the latest annual profit for Aquestive Therapeutics?
The latest annual profit of Aquestive Therapeutics is USD -7.87M
What is the registered address of Aquestive Therapeutics?
The registered address for Aquestive Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Aquestive Therapeutics website address?
The website address for Aquestive Therapeutics is www.aquestive.com
Which industry sector does Aquestive Therapeutics operate in?
Aquestive Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
BOXLBoxlight Corporation
US$ 3.1099
(51.70%)
1.84M
GDEVGDEV Inc
US$ 20.90
(46.56%)
264.44k
IVVDInvivyd Inc
US$ 1.7501
(44.64%)
37.75M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
DOYUDouYu International Holdings Ltd
US$ 7.19
(-55.31%)
1.28M
MNDRMobile health Network Solutions
US$ 0.5048
(-46.29%)
18.61M
BLUEbluebird bio Inc
US$ 4.09
(-41.90%)
5.44M
GCLGCL Global Holdings Ltd
US$ 3.83
(-31.48%)
635.26k
AXTIAXT Inc
US$ 1.57
(-31.44%)
6.66M
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
ADTXAditxt Inc
US$ 0.0922
(-22.39%)
278.25M
NVDANVIDIA Corporation
US$ 134.43
(-4.05%)
228.14M
HOLOMicroCloud Hologram Inc
US$ 1.565
(31.51%)
190.81M

AQST Discussion

View Posts
Sierra20 Sierra20 3 weeks ago
About to lift off 
👍️0
52172 52172 4 months ago
Smart man 
👍️0
52172 52172 5 months ago
Exactly
👍️0
52172 52172 5 months ago
No brainer!
👍️0
Sierra20 Sierra20 5 months ago
May breakout soon. Adding and building large position. I like their drugs.
👍️0
TechandBio TechandBio 5 months ago
Building a position here.

$AQST
👍️0
Sierra20 Sierra20 6 months ago
Seeing how fast Neffy maker moved AQST will make the same move.
👍️0
Sierra20 Sierra20 7 months ago
NEFFY is approved. Bad news for AQST very behind
👍️0
Sierra20 Sierra20 7 months ago
Selloff coming
👍️0
52172 52172 7 months ago
Not true
👍️0
Sierra20 Sierra20 7 months ago
Nothing. No updates on Libervant after approval. Now Anaphylm won’t be available for 2 more years.
👍️0
52172 52172 8 months ago
Keep dropping were not done buying!
👍️0
52172 52172 8 months ago
Huge buy opp!
👍️0
Sierra20 Sierra20 9 months ago
It’s heading back to $2. Stop the bleeding please! drug approved but not ready to sell wtf is that? Next earnings will be brutal.
👍️0
PonkenPlonken PonkenPlonken 10 months ago
added. Great science and beautiful chart.
Offerings became bullish.. dont you know?
👍️0
52172 52172 10 months ago
Is a bargain
👍️0
Monksdream Monksdream 10 months ago
AQST under $5

👍️0
52172 52172 10 months ago
Big turn around imminent
👍️0
52172 52172 11 months ago
Yessir absolutely
👍️0
Monksdream Monksdream 11 months ago
In other words you’re confident about this one from the clinical stage drug discovery sector
👍️0
52172 52172 11 months ago
Not for long
👍️0
Monksdream Monksdream 11 months ago
AQST under $5
👍️0
glenn1919 glenn1919 11 months ago
AQST................................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 11 months ago
AQST new 52 week hi
👍️0
glenn1919 glenn1919 12 months ago
AQST...........................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
I HATE YOU NOW..LOL
👍️0
Monksdream Monksdream 12 months ago
AQST new 52 week high
👍️0
glenn1919 glenn1919 12 months ago
AQST.....................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
52172 52172 12 months ago
Headed much higher!
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
AQST..EXIT...MASSIVE PLAY
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
AQST...BREAKING 4 BUCKS...BEAST
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
AQST...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
AQST...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
AQST monster bio by the master trend
👍️0
glenn1919 glenn1919 12 months ago
AQST.......................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 12 months ago
AQST new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
AQST...NEXT BIO WEEKLY BEAST
👍️0
52172 52172 1 year ago
Just the beginning
👍️0
Monksdream Monksdream 1 year ago
AQST new 52 week high
👍️0
Sierra20 Sierra20 1 year ago
Offering coming probably soon.
👍️0
Monksdream Monksdream 1 year ago
AQST new 52 week high
👍️0
shankapotamus shankapotamus 2 years ago
Initiating this one. Fantastic turnaround by company leadership. Look at the ER from last night and see for yourself.
👍️0
trendzone trendzone 2 years ago
Toxic slobs is more like it.
👍️0
crudeoil24 crudeoil24 2 years ago
On going S-3 shelf placement!

AQST
👍️0
crudeoil24 crudeoil24 2 years ago
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022
👍️0
The Night Stalker The Night Stalker 3 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=aqst%20&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 3 years ago
me=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 3 years ago
nice
👍️0
The Night Stalker The Night Stalker 3 years ago
like this
👍️0
The Night Stalker The Night Stalker 3 years ago
strange POS
👍️0

Your Recent History

NASDAQ
AQST
Aquestive Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads